Overview: Tacrolimus Level 2 TestIntroduction: The Tacrolimus Level 2 Test measures tacrolimus levels to optimize transplant therapy, preventing rejection. Following 2023 AST guidelines, it uses biochemical methods for high specificity, supporting drug monitoring. This test is critical for guiding therapy adjustments and improving outcomes in biochemistry for transplant patients.
Other Names: Tacrolimus Assay, FK506 Level Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for therapeutic drug monitoring.
Historical Milestone: Tacrolimus monitoring began in the 1990s with transplant therapy. Biochemical methods improved in the 2000s, enhancing precision.
Purpose: Measures tacrolimus levels to optimize transplant therapy, guides dosing, and prevents rejection.
Test Parameters: 1. Tacrolimus Level
Pretest Condition: No fasting required. Collect whole blood. Report history of transplant or immunosuppressive therapy.
Specimen: Whole Blood (EDTA, 2-5 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document transplant history, rejection episodes, or immunosuppressive therapy. Include current medications, especially tacrolimus.
Consent: Written consent required, detailing the tests purpose, transplant therapy implications, and risks of sample collection.
Procedural Considerations: Uses liquid chromatography-mass spectrometry (LC-MS) to measure tacrolimus levels. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for transplant monitoring.
Factors Affecting Result Accuracy: Improper sample storage or timing of collection relative to dosing can affect results. Drug interactions may alter levels.
Clinical Significance: Therapeutic tacrolimus levels confirm effective immunosuppression, guiding dose adjustments. Suboptimal levels may indicate risk of rejection or toxicity.
Specialist Consultation: Consult a transplant specialist or pharmacologist for result interpretation and dosing adjustments.
Additional Supporting Tests: Kidney function tests, CYP3A5 genotyping, or rejection biomarkers to monitor transplant health.
Test Limitations: Non-specific for rejection causes; clinical correlation is needed. Sample timing affects accuracy.
References: AST Transplant Guidelines, 2023; Transplantation, Staatz CE, 2022.
